NewTimeSpace News: FriendTimes announced on 20 July that the Group expects to record a profit of approximately RMB 68 million to RMB 74 million during the reporting period, representing a year-on-year growth of roughly 67% to 82%.
NewTimeSpace News: REFIRE (02570.HK) announced that Lin Qi, Chairman, Executive Director and CEO, has signed a voluntary lock-up undertaking. He will not sell, pledge or otherwise dispose of all 11,834,272 H Shares held directly by him from the date of this announcement up to 31 March 2028, which account for 100% of his direct shareholdings in the Company.
NewTimeSpace News: Lee & Man Paper announced on 20 July that the Group expects to record a profit of approximately HK$1.33 billion to HK$1.39 billion for the six months ended 30 June 2026.
HKIC's 2025 Annual Report reveals total assets of HKD 69.7 billion, with investment income and operating profit surging by over 170% to HKD 6.46 billion and HKD 6.32 billion, respectively, alongside a 14% portfolio net IRR. By June 2026, HKIC had backed over 200 projects, with 87% concentrated in hard tech, life/health tech, and green tech. Its global footprint expanded rapidly, with overseas investments jumping to 25%. The capital leverage ratio improved to 1:8, generating substantial local economic impact through robust job creation, increased commercial real estate demand, and extensive university collaborations.
NewTimeSpace News: July 17, 2026, CHINA PPT INV(00736.HK) released its Annual Report for the period ended March 31, 2026, Total Revenue stood at HKD 63.11 million, increased by 17.9% YoY.
NewTimeSpace (newtimespace.com) reported that on July 20, 2026, the semiconductor theme in Hong Kong stocks rebounded with volatility, and HUA HONG GRACE (01347.HK) rose in choppy trading. As of 13:30, the stock was quoted at HKD 142.500, up 2.74%.
NewTimeSpace (newtimespace.com) reported that on July 20, 2026, the humanoid robot theme fluctuated weaker, while Midea Group(00300.HK) fluctuated higher. As of 13:19, the stock was quoted at HKD 94.250, up 2.17%.
NewTimeSpace News: CHINASOFT INT'L (00354.HK) announced on 20 July that it has signed a token revenue sharing and joint innovation cooperation agreement with Moonshot AI and jointly set up the FDE Innovation Lab, focusing on enterprise-grade Agentic AI for industries including energy and power. The two parties will share revenue generated from token consumption and derivative income via a token split model. Moonshot AI, developer of Kimi LLM, boasts tens of millions of monthly professional users.
NewTimeSpace News: ZHAOKE OPHTH-B (06622.HK) announced that YUVEZZI™ (2.75% carbachol & 0.1% brimonidine tartrate ophthalmic solution), its innovative drug for presbyopia, was approved by the Macao Special Administrative Region Government Drug Administration on 13 July 2026. The Group is actively applying for YUVEZZI™ to be included in the Hong Kong-Macao Medicines & Devices Connect Scheme to accelerate its clinical application in the Greater Bay Area.
NewTimeSpace News: On 20 July 2026, RoboSense (02498.HK) posted a mild uptick during morning trading. As of 11:19 a.m., the stock traded at HK$22.04, representing a 0.82% gain. The second-generation all-solid-state perception platform E2, built on the self-developed "Peacock" SPAD-SoC chip, was launched at WAIC 2026.
NewTimeSpace (newtimespace.com) News,Choice data shows that from the beginning of July 2026 to July 17,Huaan Hang Seng Internet Technology Industry ETF Initiating Feeder Fund A (019936) and Huaan Hang Seng Internet Technology Industry ETF Initiating Feeder Fund C (019937) rose by 8.60% and 8.59%, respectively.
Insilico Medicine has entered a $600 million AI drug discovery collaboration with Takeda, securing a $60 million upfront payment. The company has inked four major cross‑border deals in 2026, with a combined potential value of nearly $7 billion. HKIC’s patient capital continues to empower the firm by facilitating access to global industry resources.
NewTimeSpace (newtimespace.com) News, Choice data shows that from the beginning of July 2026 to July 17,ChinaAMC Hang Seng Internet Technology Industry ETF Initiating Feeder Fund A (013171) andChinaAMC Hang Seng Internet Technology Industry ETF Initiating Feeder Fund C (013172) rose by 8.60% and 8.72%, respectively.
NewTimeSpace News: CSTONE PHARMA-B (02616.HK) announced on 20 July that clinical data of its core asset CS2009, a first-in-class PD-1/VEGF/CTLA-4 trispecific antibody, has been accepted by ESMO Congress 2026 for two rapid oral presentations covering Phase I/II trial results in advanced NSCLC and metastatic colorectal cancer patients. Updated full data will be unveiled at the Madrid conference held from 23 to 26 October 2026. The Company reminds investors of uncertainties in the clinical development and commercialization of CS2009.
NewTimeSpace News: IMPACT THERAP-B (07630.HK) announced on 20 July that clinical data of three pipeline assets, namely senaparib, IMP1734 and IMP1707, have been accepted as poster presentations for the ESMO Congress 2026. Senaparib has been approved in China for first-line maintenance therapy of advanced ovarian cancer and included in the national medical insurance catalogue, with its European MAA filed and accepted by EMA. IMP1734 and IMP1707 are next-generation selective PARP1 inhibitors.
NewTimeSpace News: JACOBIO-B (01167.HK) announced on 20 July that its pan-KRAS inhibitor JAB-23E73 combined with nab-paclitaxel and gemcitabine completed first patient dosing in China for a Phase Ib/III clinical trial as first-line therapy for KRAS-mutant pancreatic cancer. Earlier Phase I data showed an ORR of 38.5% with favourable safety profile. AstraZeneca has obtained exclusive global rights (excluding mainland China), where the two parties co-develop and co-commercialise the candidate. The Company cautions uncertainties exist in drug development.
